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i Summary: Serum immunoreactive prolyl hydroxylase protein, galactosylhydroxylysyl glucosyltransferase
l activity and the aminoterminal propeptide of type III procollagen were measured in 20 patients with sickle
cell disease and the values were compared with those in 20 apparently healthy Nigerians. The means for the
two enzymes and serum aminoterminal propeptide of type III procollagen were significantly higher in the
! sickle cell disease patients. Significant correlations were found between the values for the two enzymes and
! the protein serum aminoterminal propeptide of type III procollagen within the sickle cell disease patients.
The data confirm that collagen formation is found in the liver, bone and other organs of patients with this
disease. The measurement of serum immunoreactive prolyl hydroxylase protein, serum galactosylhydroxylysyl
' < glucosyltransferase activity and serum aminoterminal propeptide of type III procollagen in prospective studies
r
 might be helpful in predicting hepatic, bone or diffuse fibrogenesis in sickle cell disease.
5
l
Enzyme der Kollagensynthese und Typ III-Prokollagen-Aminopropeptid im Serum nigerianischer Patienten mit
Sichelzettkrankheit
Zusammenfassung: Immünreaktives Prolylhydroxylase-Protein, katalytische Aktivität von Galaktosylhydro-
xylysyl-Glucosyltransferase und das aminoterminale Propeptid vom Typ III Prokollagen wurden im Serum
bei 20 Patienten mit Sichelzellanämie gemessen. Die Werte wurden mit denen von 20 offensichtlich gesunden
Nigerianern verglichen. Die Mittelwerte für die beiden Enzyme und das aminoterminale Propeptid von Typ
i III Prokollagen waren bei den Patienten mit Sichelzellanämie signifikant höher. Signifikante Korrelationen
} wurden zwischen den Werten für die beiden Enzyme und das aminoterminale Propeptid von Typ III
5 Prokollagen innerhalb der Sichelzellanämiepatienten festgestellt. Die Daten bestätigen, daß Kollagenbildung
; in Leber, Knochen und anderen Organen von Patienten mit dieser Erkrankung vorkommt. Die Messung der
l drei Kenngrößen bei prospektiven Studien könnte für die Vorhersage der Kollagenfaserbildung in der Leber,
in Knochen, oder diffus bei Sichelzellanämie hilfreich sein.
Introduction repeated äs often äs one may desire. Attempts have
T . t . . therefore been made to develop methods for the esti-Increased hepatic connective üssue deposition is
 mation of ^ bone> Qr diffuse co,lagen
found in many aeute and chromc dzseases of varymg
 & serum $
aetiologies (1). The extent and progress are usually
assessed by histöpathological examination of biopsy The biosynthesis of collagen involves a number of
specimens. Disadvantages of the histological exam^· enzymatic modifications, many of which are unique
ination are that the actual rate of collagen synthesis to collagens and a few other proteins with collagen-
is difficult to assess and that biopsies cannot be like amino acid sequences (2-4). Two post-transla-
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tional enzymes can be estimated in serum in the form
of immunoreactive prolyl hydroxylase protein and
galactosylhydroxylysyl glucosyltransferase activity
(5 — 11). Increased serum immunoreactive prolyl hy-
droxylase protein and serum galactosylhydroxylysyl
glucosyltransferase activity have been reported in
patients with various liver diseases (5 — 12). The two
serum enzymes correlate significantly with the respec-
tive enzyme activities in liver biopsy specimens, which
indicates that serum immunoreactive prolyl hydroxyl-
ase protein and serum galactosylhydroxylysyl gluco-
syltransferase activity may give useful Information on
actual hepatic Collagen formation (10, 12, 13).
A radioimmunoassay for the measurement of the
serum amino-terminal propeptide of type III procol-
lagen is now available (14). The procollagens are
biosynthetic precursors of various genetically distinct
collagen types. They are processed to collagens by
the enzymatic cleavage of their amino- and carboxy-
terminal extensions in the extracellular matrix (2, 4).
Increased serum aminoterminal propeptide of type
III procollagen concentrations have been found es-
pecially in several liver diseases (14,15). No data have
so far been reported concerning sickle cell disease, nör
is it known whether the collagen laid down in liver,
bone or other organs of patients with sickle cell
disease (16—19) can be detected by the measurement
of serum immunoreactive prolyl hydroxylase protein,
serum galactosylhydroxylysyl glucosyltransferase ac-
tivity and serum aminoterminal propeptide of type
III procollagen.
This communication reports our preliminary findings
in the clinical application of radioimmunoassay tech-
niques for separate determination of serum immuno-
reactive prolyl hydroxylase protein and serum amino-
terminal propeptide of type III procollagen in
patients with sickle cell disease. The serum galactosyl-
hydroxylysyl glucosyltransferase activity was also
measured in the same patients.
Patients and Methods
A total of twenty homozygous sickle cell patients, age 5—18
years, were examined. A reference control group of healthy
Nigerians, sex- and age-matched, was also included in the
investigation. Patients were first seen in the outpatient depart-
ment of the University of Ife Teaching Hospitals, Ile-Ife. All
the patients were asymptomatic at the time blood samples were
taken for the assays; the only complaints were of moderate
lassitude. Icterus was mild, but the liver was palpable in 11 or
55% of these patients. The diagnosis of sickle cell disease was
based on clinical observation and confirmed by the finding of
a haemoglobin SS pattern on cellulose acetate strip electropho-
resis in the laboratory, after preliminary investigation had re-
vealed very low haemoglobin and haematocrit values. All the
control subjects had haemoglobin AA and no evidence of liver
disease.
In both patients and controls, sera were separated after allowing
the blood samples to coagulate for 2 h at room temperature
and were stored frozen at — 20 °C until assayed for serum
immunoreactive prolyl hydroxylase protein and serum amino-
terminal propeptide of type III procollagen total protein levels.
All serum samples were either aliquots of samples taken for
diagnostic purposes or were obtaine<^ with the pennission of
the patients.
Serum immunoreactive prolyl hydroxylase protein was mea-
sured with a dkect radioimmunoassay based on the displace-
ment of radioactively labelled human prolyl hydroxylase pro-
tein from its antibody by the non4abelled human enzyme
protein and the precipitation of the enzyme protein-antibody
complex by a ceUulose-bound second antibody (11, 12). Pure
human prolyl hydroxylase protein was used äs the Standard
enzyme. The samples were assayed in düplicates and serum
enzyme protein concentrations were expressed äs mg per liter.
Serum aminoterminal propeptide of type III procollagen was
measured using a radioimmunoassay kit (Behringwerke AG,
Germany) based on the displacement of radioactively-labelled
type III aminoterminal propeptide and the subsequent precipi-
tation of the peptide-antibody complex by a second antibody
(13). Serum galactosylhydroxylysyl glucosyltransferase activity
was measured by the method of Myllyla et al. (20), äs modified
for human serum samples (21).
A Standard hospital laboratory method was used for the deter-
mination of serum alanine aminotransferase in 15 of our
patients. It proved impossible to assay alanine aminotransferase
in the remaining 5 patients äs the serum samples were too
small.
The statistical significances of the differences between two
means were calculated by Student*s t-test and the correlations
were determined by linear regression analysis.
Results
The mean serum immunoreactive prolyl hydroxylase
protein concentration for thie 20 control subjects was
1.16 ± 0.12 (SD) mg/l, the serum galactosylhydroxy-
lysyl glucosyltransferase activity 0.33 ± 0.03 U/l and
the serum aminoterminal propeptide of type III pro-
collagen concentration 11.84 + 1.45 g/l. The corre-
sponding upper normal limits defined äs the mean
+ 2 SD, were thus 1.40 mg/1, 0.39 U/l and 14.74 g/l.
Any individual values exceeding the upper normal
limits were considered patholpgical (fig. l a, b and c).
The mean values for serum immunoreactive prolyl
hydroxylase protein (1.62 + 0.38 mg/1), serum
galactosylhydroxylysyl glucosyltransferase activity
(0.56 ± 0.20 U/l) and serum aminoterminal propep-
tide of type III procollagen (21.23 ± 14.00 g/l) were
all elevated highly significantly (p < 0.001) in the
cases of the sickle cell disease compared to the nor-
mals. Fifteen patients or 75 percent of the cases
investigated had serum immunoreactive prolyl hy-
droxylase protein and serum galactosylhydroxylysyl
glücosyltran$ferase activity values exceeding «the up-
per normal limits (fig. l a and'l c), while 11 patients
or 55 percent had serum aminoterminal propeptide
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Tab. 1. Correlation between serum immunoreactive prolyl hy-
droxylase protein (S-IRPH), serum galactosylhydroxy-
lysyl glucosyltransferase activity (S-GGT), serum ami-
noterminal propeptide of type III procollagen
(S-Pro(III)-N-P) and alanine aminotransferase (ALAT)
in patients with sickle cell disease.
Pair of assays r p
S-IRPH and S-GGT
S-IRPH and S-Pro(III)-N-P
S-GGT and S-Pro(III)-N-P
S-IRPH and ALAT
S-GGT and ALAT
ALAT and S-Pro(III)-N-P
0.676
0.420
0.699
0.628
0.647
0.387
< 0.001
<0.05
< 0.001
< 0.001
< 0.001
Fig. l a. Serum immunoreactive prolyl hydroxylase in controls
and patients with sickle cell disease. The horizontal
line indicates the mean -f 2 SD of the controls.
Fig. l b. Serum procollagen III-amino-propeptide in controls
and patients with sickle cell disease. The horizontal
line indicates the mean -h 2 SD of the controls.
Fig. l c. Serum collagen glucosyltransferase catalytic concen-
tration in controls and in patients with sickle cell
disease. The line drawn horizontally indicates the
mean -h 2 SD of the controls.
of type III procollagen values exceeding the upper
normal limit (fig. l b). The data of the present investi-
gation confirm the results of earlier morphological
studies, which demonstrated collagen fibers and base-
ment membranes in the livers and other organs of
patients with sickle cell disease (16—19). All 11
patients who had elevated sefum aminoterminal pro-
peptide of type III procollagen concentrations also
had increased serum immunoreactive prolyl hy-
droxyl se protein and serum galactosylhydroxylysyl
glucosyltransferase activity values.
The mean serum alanine aminotransferase in 15
patients with measured serum collagen enzymes and
type III prpcollagen aminopropeptide was 15.53 ±
13.9 U/l. Grossly elevated values of alanine amino-
transferase were observed in 3 of these 15 cases of
sickle cell disease. All 3 patients had increased serum
immunoreactive prolyl hydroxylase protein, serum
galactosylhydroxylysyl glucosyltransferase activity
and serum aminoterminal propeptide of type III pro-
collagen values,
Significant correlations were found between various
pairs of values from the four tests, but not between
the serum aminoterminal propeptide of type III pro-
collagen and alanine aminotransferase test within the
group of patients studied (tab. 1).
Discussion
The data reported here clearly demonstrate that
serum immunoreactive prolyl hydroxylase protein,
serum galactosylhydroxylysyl glucosyltransferase ac-
tivity and serum aminoterminal propeptide of type
III procollagen are elevated in cases of sickle cell
disease. A high correlation was found between all
three serum markers of collagen biosynthesis, within
the group of patients studied, suggesting diffuse fibro-
genesis. High correlations have previously been found
between the three serum markers in patients with
various liver diseases (6, 9, 11), and are now demon-
strated in sickle cell disease. Correlation of the two
serum enzymes and serum aminoterminal propeptide
of type III procollagen with tests of liver function
have been reported earlier (10,11,13), and here there
were significant correlations between the two serum
enzymes of collagen and serum alanine aminotrans-
ferase, but a very week correlation was found between
alanine aminotransferase and serum aminoterminal
propeptide of type III procollagen. It thus seemed
likely that the two serum enzymes and serum amino-
terminal propeptide of type III procollagen primarily
reflect in sickle cell disease the actual changes in
hepatic, bone or spieen collagen formation. Other
liver enzyme assays such s aspartate aminotransfer-
ase, alkaline phosphatase and γ-glutamyl transferase
may have been very helpful but these were not done
due to lack of enough serum samples.
It may be noted that none of these three markers
of collagen biosynthesis is entirely specific for liver
involvement in sickle cell disease, so diffuse fibrotic
changes in other organs, such s the spieen or bone
of these patients, may also contribute to the elevated
values of these enzymes of collagen synthesis and
serum aminoterminal propeptide of type III procolla-
gen.
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